NASDAQ:CTOR

Citius Oncology (CTOR) Stock Price, News & Analysis

Citius Oncology logo
$0.56 +0.00 (+0.29%)
As of 11:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Citius Oncology Stock (NASDAQ:CTOR)

Advanced

Key Stats

Today's Range
$0.55
▼
$0.57
50-Day Range
$0.50
▼
$1.14
52-Week Range
$0.49
▼
$1.83
Volume
15,584 shs
Average Volume
153,751 shs
Market Capitalization
$51.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing oncology therapies. Its lead product is LYMPHIR (denileukin diftitox-cxdl), an immunotherapy approved in the United States for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

LYMPHIR targets cells expressing the interleukin-2 receptor and is intended to treat certain forms of CTCL, a rare non-Hodgkin lymphoma that affects the skin. The company’s commercial activities are centered on making the therapy available to eligible patients in the U.S.

Citius Oncology became a publicly traded company following a business combination involving Citius Pharmaceuticals’ oncology subsidiary and TenX Keane Acquisition. Leonard Mazur, a co-founder and longtime executive of Citius Pharmaceuticals, has served as Citius Oncology’s chief executive officer.

AI Generated. May Contain Errors.

Citius Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

CTOR MarketRank™: 
0.52915471801 of 5 stars

Citius Oncology scored higher than 11% of companies evaluated by MarketBeat, and ranked 1595th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Citius Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Citius Oncology has only been the subject of 1 research reports in the past 90 days.

  • Read more about Citius Oncology's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Citius Oncology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Citius Oncology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Citius Oncology has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Citius Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    0.24% of the float of Citius Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Oncology has a short interest ratio ("days to cover") of 1.19, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Oncology has recently decreased by 11.23%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Citius Oncology does not currently pay a dividend.

  • Dividend Growth

    Citius Oncology does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Citius Oncology this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Citius Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.82% of the stock of Citius Oncology is held by insiders.

  • Percentage Held by Institutions

    70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Citius Oncology's insider trading history.
Receive CTOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTOR Stock News Headlines

Citius Oncology (NASDAQ:CTOR) Shares Climb 1.8% - Should You Buy?
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Headlines

CTOR Stock Analysis - Frequently Asked Questions

Citius Oncology's stock was trading at $1.00 at the beginning of 2026. Since then, CTOR shares have decreased by 44.2% and is now trading at $0.5580.

Citius Oncology, Inc. (NASDAQ:CTOR) announced its quarterly earnings results on Friday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $1.49 million for the quarter, compared to analyst estimates of $2.50 million.

Top institutional shareholders of Citius Oncology include State Street Corp (0.05%) and Private Advisor Group LLC (0.03%).

Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/14/2026
Today
11/19/2026
Next Earnings (Estimated)
12/17/2026
Fiscal Year End
9/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CTOR
Previous Symbol
NASDAQ:CTOR
CIK
1851484
Fax
N/A
Employees
285
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.76 million
Net Margins
N/A
Pretax Margin
-645.66%
Return on Equity
-102.98%
Return on Assets
-43.49%

Debt

Debt-to-Equity Ratio
0.25
Current Ratio
0.73
Quick Ratio
0.34

Sales & Book Value

Annual Sales
$7.11 million
Price / Sales
7.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
1.04

Miscellaneous

Outstanding Shares
92,981,000
Free Float
83,850,000
Market Cap
$51.98 million
Optionable
N/A
Beta
3.56
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:CTOR) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners